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ABSTRACT
miRDeep and its varieties are widely used to
quantify known and novel micro RNA (miRNA) from
small RNA sequencing (RNAseq). This article de-
scribes miRDeep*, our integrated miRNA identifica-
tion tool, which is modeled off miRDeep, but the
precision of detecting novel miRNAs is improved
by introducing new strategies to identify precursor
miRNAs. miRDeep* has a user-friendly graphic
interface and accepts raw data in FastQ and
Sequence Alignment Map (SAM) or the binary
equivalent (BAM) format. Known and novel miRNA
expression levels, as measured by the number of
reads, are displayed in an interface, which shows
each RNAseq read relative to the pre-miRNA
hairpin. The secondary pre-miRNA structure and
read locations for each predicted miRNA are
shown and kept in a separate figure file. Moreover,
the target genes of known and novel miRNAs are
predicted using the TargetScan algorithm, and the
targets are ranked according to the confidence
score. miRDeep* is an integrated standalone appli-
cation where sequence alignment, pre-miRNA sec-
ondary structure calculation and graphical display
are purely Java coded. This application tool can be
executed using a normal personal computer with 1.5
GB of memory. Further, we show that miRDeep*
outperformed existing miRNA prediction tools
using our LNCaP and other small RNAseq
datasets. miRDeep* is freely available online at
http://www.australianprostatecentre.org/research/
software/mirdeep-star.
INTRODUCTION
Micro RNA (miRNA) is a class of small, non-protein–
coding RNA (ncRNA) that is important in normal physi-
ology, which includes development and tissue-specific
processes in many eukaryotic systems. Mature miRNAs
are typically generated from longer primary and precursor
miRNA or from intronic RNA (1, 2). miRNA typically
mediate its biological effects through translation inhib-
ition or, in some instances, by RNA degradation
through the RNA-induced silencing complex (RISC) (3).
It is thought that, similar to other diseases, dysregulated
miRNA expression in prostate cells can lead to prostate
cancer progression. Indeed, 26 miRNAs have been found
to be deregulated in prostate cancer (4). The prostate is
regulated by the male hormones, androgens, and the
action of androgens is mediated by its cognate receptor,
the androgen receptor (AR), which is a ligand-dependent
transcription factor. Concomitantly, androgens are also
important in prostate cancer progression (5). Conse-
quently, much research in the prostate cancer field has
focused on genes that are targeted by the AR signaling
axis in this disease. However, other than the TMPRSS2–
ERG fusion gene (6), which appears to be overexpressed
in many prostate cancers (7), the other bona fide AR
target genes that are important in prostate cancer progres-
sion remain elusive. Two recent microarray studies suggest
that at least 27 known miRNAs are androgen regulated in
prostate cancer cells (8,9), although this number is likely
to increase as data emerge from next-generation se-
quencing platforms that have already identified many
novel prostate expressed miRNA (10–12).
The advent of high-throughput sequencing technology
has provided researchers an unbiased opportunity to sys-
tematically identify most, if not all, of the miRNA that are
expressed in the transcriptome. Thus, determining levels
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of known and novel miRNA from small RNA sequencing
(RNAseq) data is an important issue in the era of next
generation sequencing. Although there are several miRNA
profiling applications such as miRanalyzer (13),
miRTRAP (14) and MIReNA (15), these methods rely
on known miRNAs and a user’s training data.
Consequently, these results largely depend on known
miRNA data and the classification algorithm. In
miRDeep (16), prediction of miRNA from sequenced
reads is output as a probability from the log odds ratio.
More recently, miRDeep2 was developed (17), which
offers similar improved mature miRNA prediction algo-
rithms as those used in our miRDeep* tool. Indeed,
miRDeep2 has shown great predictive ability of bona
fide miRNA by comparing between datasets where the
miRNA biogenesis pathway was or was not active.
miRDeep2 has also adopted other improved
functionalities such as a graphics output of the predicted
secondary structure of pre-miRNA. However, miRDeep2
and other similar miRNA prediction tools are dependent
on other software such as pre-miRNA secondary structure
prediction and/or genome mapping. Consequently, we
have developed miRDeep*, which is an integrated tool
that can be used to identify novel miRNA from raw
RNAseq reads, as well as quantifying miRNA expression.
Further, miRDeep* offers a user-friendly graphical output
that displays the location of the sequenced reads in the
pre-miRNA hairpin structure. All components of
miRNA identification in this application, such as
sequence alignment (18, 19) and RNA folding (20), is
purely Java coded. In addition, miRDeep* incorporates
the widely used TargetScan program (21–23). The
targets of both known and novel miRNA are predicted
using one click. Finally, miRDeep* is compatible for use
with other species to identify both novel and known
miRNAs from raw small RNAseq data.
In this study, we have used the Illumina Genome
Analyser II to sequence the androgen-regulated small
RNA transcriptome of LNCaP prostate cancer cells. We
demonstrate using this dataset that miRDeep* has higher
precision in detecting novel miRNA from the total
number of predictions when compared with other avail-
able miRNA prediction tools, such as miRDeep,
miRDeep2, miRanalyzer, miRTRAP and MIReNA.
MATERIALS AND METHODS
Cell culture
The LNCaP prostate cancer cell line was obtained from
American Type Culture Collection. Cells were maintained
in RPMI 1640 media (Life Technologies, Carlsbad, CA,
USA) supplemented with 10% fetal calf serum (Life
Technologies). For steroid treatment experiments, cells
were cultured until approximately 70% confluent and
then maintained in media containing 10% charcoal-
stripped serum (HyClone, Denver, CO) for 48 h,
followed by the addition of 1 nM R1881 or ethanol
(Mock control) for an additional 48 h.
Small RNAseq
RNA was isolated using the miRVana RNA isolation kit
(Life Technologies). The RNA was prepared for
sequencing using the Illumina Small RNA Sample Prep
Kit. The small RNA libraries were sequenced on the
Illumina Genome Analyzer II at the Genome Sciences
Centre (Vancouver, BC) as described (24).
miRDeep* strategy for prediction of miRNA
The miRDeep* pipeline for the prediction of miRNA
from small RNAseq data is summarized in Figure 1a.
Genomic mapping is one of the most time-consuming pro-
cedures. To reduce mapping time, all sequence reads that
are the same are first aggregated, and representative reads
are then mapped to the genome. Moreover, reads that are
outside the range of miRNA length (18–23 nucleotides)
are excluded before genomic mapping. Mapped reads
are then output in a SAM format (25). Alternatively,
pre-generated SAM files by other genomic tools can be
used for integration into the miRDeep* pipeline.
The miRDeep (16) algorithm aggregates reads that
align to the same strand within 30 bp of each other to
form a read coverage region. However, miRDeep*
adopts a different strategy to excise the potential precur-
sor locus range. In miRDeep, if the coverage region is
greater than 30 bp, then both sides of the coverage
region are extended by 22 bp for the precursor miRNA
(Figure 1b; Case 1). However, if the coverage region is
less than 30 bp, then one side of the coverage is extended
by 22 bp and the other side is extended to ensure that the
potential miRNA precursor totals 110 bp in length
(Figure 1b; Case 2). The highest expressed read is con-
sidered as the mature miRNA.
In miRDeep*, the highest expressed read at the poten-
tial miRNA locus is also considered as the mature
miRNA. One side of the read is extended by 22 bp (for
miRNA offset RNA), and the other side of the read is
extended by 15 bp (to account for the loop region) and
the mature RNA* that has the same number (n [base
pairs]) of nucleotides as the mature miRNA, as well as
by 22 bp for the miRNA offset RNA (Figure 1d).
Consequently, miRDeep* can prevent some false nega-
tives that might arise from improper precursor regions
that can be selected for miRDeep. This strategy is
similar to that of the recently published miRDeep2 algo-
rithm (Figure 1c).
miRDeep* application and interface
This application tool has been developed in the
platform-independent computer language, Java. As a
result, it can run in Linux, MS Windows and MacOS.
To further reduce the memory requirement for
miRDeep*, we have implemented a compact Java
version of the Bowtie alignment algorithm (18) where
the index files are loaded chromosome by chromosome,
instead of loading the entire chromosome index at once.
Using this approach, it takes about 1 h to align 3 million
reads using a PC comprising 2.5GHz CPU and 4.00 GB
memory (RAM). From the raw data (FastQ format),
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miRDeep* will identify novel miRNAs and also generate
all expression data for known and novel miRNAs.
The miRDeep* interface has four parts:
(1) User input parameters: The Illumina Deep
sequencing platform adapters are the default
adapter sequence for miRDeep*. The default length
of miRNAs is set at 18–23 nucleotides. Low-quality
reads are filtered out at the alignment stage. A read
with more than a 20 phred score (which represents
99% base call accuracy) is considered to be a good
read. We also filter out multi-mapping reads with
alignments to more than 100 genomic loci. This par-
ameter can be changed at the user’s discretion.
miRDeep* uses other mapped reads at that loci to
determine the strength of the prediction (Figure 2).
Reads mapping to tRNA, sno-RNA and piRNA are
also excluded. Currently, miRDeep* is unable to
handle technical or biological mismatches. The
score is based on the probabilistic score of the po-
tential miRNA precursor that was previously
described (26, 27). miRDeep* also incorporates a
tick box for to allow miRDeep* users to alternatively
use the original miRDeep algorithm.
(2) Input file area for raw data (FastQ), pre-aligned files
(SAM or BAM) or results (generated by miRDeep*)
files: In the first step, input reads are converted to
FastQ format (25) for genomic alignment. We have
implemented our small memory consuming Bowtie
algorithm (18) for the alignments because
miRDeep* is targeted at ordinary PCs with limited
memory capacities. Users can also employ alternative
alignment tools, such as soap2 (19). The pre-aligned
BAM/SAM file is inputted into the textbox.
(3) A progress bar: To monitor the progress of
miRDeep*, the percentage of completion of
genomic mapping and identifying miRNA are dis-
played at the all procedure stages.
(4) Results display: There are five output files located in
the same directory as the input data file. These files
are as follows:
(i) xxx.result: Contains information such as chromo-
somal location, expression levels, pre-miRNA se-
quences, secondary structure of pre-miRNA and
mature miRNA sequences for miRDeep*-predicted
miRNA. The miRNA ID for predicted miRNA are
assigned to known miRNA if the mature miRNA
sequences match. Pre-miRNA secondary structure
prediction is rewritten in Java based on the Vienna
algorithm (28). All default parameters are used for
prediction, but in the output figure, the RNA sec-
ondary structure is shown with G–U pairing.
(ii) xxx.cluster: Contains information for clusters of
predicted miRNA. All mature miRNA sequences
in a cluster are from the same reads. In the file,
Figure 1. miRNA prediction strategy for miRDeep, miRDeep2 and miRDeep*. (a) miRNA prediction pipeline for miRDeep*. Step 1 involves
mapping sequences to the genome to produce a SAM file. In step 2, aggregated RNAseq reads are assessed for pre-miRNA secondary structure
potential. (b) The two different miRNA prediction strategies (case 1 and case 2) for miRDeep. (c) and (d) Modified miRNA prediction strategy for
miRDeep2 and miRDeep*.
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the first column refers to miRNAs that share the
same sequence reads, and the second column
refers to the number of shared reads.
(iii) xxx.sam: All reads in the FastQ file are mapped to a
coordinate sorted SAM file. A new attribute, called
XS, is created, which records the copy number of a
sequenced read.
(iv) xxx.knownMiR: Contains two columns, one
refers to the miRNA ID and the other refers
to the number of sequenced reads mapping to
the genomic region where the miRNA is located.
(v) xxx.purified.fa: Contains purified reads in FastQ
format based on three types of filtering. (i) Reads
that do not conform to mature miRNA length
(18–23 bp). (ii) Ambiguous nucleotides ‘N’ appear
in the reads. (iii) The quality of a read is lower
than the threshold. To reduce mapping time, reads
that have the exact sequence are aggregated and the
number is put in the second item of the description
line of the fasta format.
The expression level of each predicted miRNA is
determined by the number of reads covering the mature
miRNA region. miRDeep* accounts for miRNA isoforms
by including variants that share 90% sequence homology
with the mature miRNA.
Figure 2. The input/output interface for miRDeep*. Parameters are customizable for the genome build, use of the original mirDeep algorithm
(miRDeep), filtering out platform-specific adapter sequences (Adapter), the miRNA length (miR Length), the minimum read quality (min phred), the
maximum number of loci mapped for a particular read (max multimap), the minimum number of reads (min reads) and the minimum prediction
score (min score). The location of the mature miRNA and the number of reads relative to the pre-miRNA secondary structure can also be displayed
by simply clicking on the miRNA of choice. On the pop-up window, target genes can be predicted for current sequence by clicking ‘Target genes’.
The sequence in the top textbox can be replaced and click ‘RNA structure’ to regenerate RNA secondary structure. Note that mature sequence needs
to be in upper case.
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miRDeep* output visualization
miRDeep*-predicted miRNA is shown in a pop-up
window by clicking the miR ID in the first column of
the output table (Figure 2). The actual sequence reads
are also displayed in the pre-miRNA (Figure 2). The
mature miRNA sequence is shown in red text. Users can
also change the sequence in the top textbox to see the
pre-miRNA secondary structure by clicking the ‘RNA
structure’ button in the pop-up window. The targets can
be obtained by clicking ‘Target genes’. The details are
given below.
Prediction of target genes
There are many miRNA target prediction tools, such as
Diana microT (29), miRanda (30), TargetMiner (31) and
MirTarget (32). In this application, we use one of the most
commonly used prediction tools, TargetScan, (21) to
predict targets for identified known and novel miRNAs.
The list of target genes is ranked in ascending order of the
PCT (preferentially conserved targeting) value, which
shows the conservative degree of target binding sites
(23). Context score (22) is also output in the list.
Context score shows the predicted efficacy of targeting.
When a gene/transcript has more than one miRNA
binding site, the summation of PCT is used for ranking.
The percentile of a binding site is the percent point of the
binding site in a descending order of context score of all
binding sites of a miRNA.
Stem-loop reverse transcription TaqMan polymerase
chain reaction
Novel miRNAs predicted by miRDeep* from small
RNAseq were validated using the miRNA-specific
stem-loop reverse transcription (SL-RT) TaqMan poly-
merase chain reaction (PCR) (33). Briefly, RT was
carried out on 1 mg of DNAse I (Life Technologies)-
treated total RNA and using 1 unit of superscript III as
per the manufacturer’s instructions (Life Technologies).
cDNA synthesis was performed at 42C.
Oligonucleotides used in RT for each miRNA are
detailed in Supplementary Table S1. TaqMan PCR was
carried out using the TaqMan Universal PCR Master Mix
(Applied Biosystems, Mulgrave, VIC, Australia) as per the
manufacturer’s instructions, but with modifications as
described previously (34), and using primer annealing tem-
peratures of 55C. TaqMan probes and PCR primers are
detailed in Supplementary Table S1. Gene expression was
quantified against a standard curve of synthetic mature
miRNA oligonucleotides (Sigma-Aldrich, Castle Hill,
NSW, Australia). Random hexamer generated cDNA
was used as a negative control for SL-RT TaqMan PCR
specificity and for assessing RPL32 gene expression for
normalizing miRNA expression. Quantitative RT–PCR
for RPL32 was carried out using the Sybr Green PCR
mastermix (Applied Biosystems) as described previously
(35). Data are represented as the standard error mean
from three independent RNA extractions.
Qualitative RT–PCR
Qualitative RT–PCR was carried out to detect
pre-miRNA as further validation of miRDeep*-redicted
mature miRNA. RT was performed as per SL-RT
TaqMan PCR, but using random hexamer oligonucleo-
tides, and cDNA synthesis was performed at 50C. PCR
was carried out using platinum taq DNA polymerase (Life
Technologies), a 60*C primer annealing temperature and
40 cycles of PCR. A negative RT control was used to
ensure that genomic DNA was not amplified as
pre-miRNAs are intron less. All primer sequences are
detailed in Supplementary Table S2. Data are represented
as the mean ± standard error from RNA extracted from
three independently treated cells. Two tailed t-testing was
used to assess for significant differences in expression.
RESULTS
Benchmarking of miRDeep* sensitivity and specificity
in detecting mature miRNA against miRDeep,
miRanalyzer, miRTRAP and MIReNA
Androgens are important mediators of prostate cancer
physiology. Thus, we have used the most widely studied
androgen-responsive prostate cancer model, the LNCaP
cell line, to investigate miRNA that are downstream of
the AR signaling axis. In total, 3 937 673 and 7 791 811
small RNAseq reads were obtained from mock
(ethanol)- and R1881 (synthetic androgen)-treated
LNCaP cells, respectively. The miRNA predictive
capacity of miRDeep* was then compared against the
popular miRDeep2, miRDeep, miRanalyzer, miRTRAP
and MIReNA. miRNA prediction algorithms. The
miRNA detection threshold for miRDeep2, miRDeep
and miRDeep* was set at the previously recommended
score of 0 (16). In total, miRDeep*-predicted 208 (mock
dataset) and 237 (R1881) miRNAs, whereas miRDeep2-
predicted 272 (mock dataset) and 320 (R1881 dataset)
miRNAs, miRDeep-predicted 203 (mock dataset) and
235 (R1881 dataset) miRNAs and miRanalyzer-predicted
1063 (mock dataset) and 1321 (R1881 dataset) miRNA
(Figure 3A, Table 1 and Supplementary Table S3). For
miRDeep*, miRDeep2 and miRDeep, the majority of the
highest scoring miRNAs, and thus more likely to be bona
fide miRNA, were known miRNA that are already in the
miRBase database v13. In contrast, miRanalyzer had a
higher proportion of novel miRNA with high number of
reads when compared with miRDeep*, miRDeep2 and
miRDeep. MiRTRAP predicted similar number of
miRNAs with miRDeep2, but the precision is lower
than miRDeep. MIReNA predicted a small number of
miRNAs, but a few of them are not in miRBase (36).
Both the precision and recall of MIReNA are lower
than miRDeep*.
An analysis was then performed to compare the cap-
ability of miRDeep* in detecting known miRNA using the
same datasets with that of the miRDeep, miRDeep2,
miRanalyzer, miRTRAP and MIReNA programs.
MiRanalyzer predicted approximately five times more
miRNA from our LNCaP dataset compared with
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Figure 3. (a) Vertical axis represents the log scores of predicted miRNAs obtained from miRNA prediction algorithm. The horizontal axis lists
predicted miRNAs in descending order of score. Green lines show the predicted miRNAs that are known from miRBase. The red lines show the
predicted miRNAs not listed in miRBase (i.e. novel miRNAs). The vertical axis is log scale, because the score difference across predicted miRNAs is
huge. Since miRanalyzer, miRTRAP and MIReNA do not provide scores, the vertical axes represent the number of reads in the predicted miRNA.
The number of predicted miRNAs shown in the figure is reduced to match the other algorithms. (b) Vertical axis represents the log fold changes after
anti-dicer induced. The horizontal axis lists predicted miRNAs in descending order of folder changes.
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miRDeep*, miRDeep2 and miRDeep (Table 1). However,
the precision, which is measured relative to known
miRNA (37), of miRanalyzer-predicted miRNA was
only 19.76 and 20.23%. This indicates that 80% of the
miRNA predicted by miRanalyzer are novel and without
any validation. miRDeep* and miRDeep predicted much
fewer miRNA; however, the precision for both algorithms
was >70%, with miRDeep* having a 2.9 and 5.8% higher
precision for the mock- and R1881-treated datasets, re-
spectively (Table 1). miRDeep* also slightly outperformed
miRDeep in detecting validated miRNA using the same
datasets with 5.5 and 6.7% higher recall. Interestingly,
miRDeep2 had lower precision (76.47 and 71.56%)
compared with the original miRDeep and miRDeep*.
Conversely, miRDeep2 has higher recall ratio (86.67 and
80.35%) than miRDeep and miRDeep* in terms of recall
(Table 1).
Like most miRNA prediction tools, we have set a
threshold to stop mapping a read when the number of
mapped genomic loci exceeds this threshold (default
threshold is 101). As shown in Table 2, uniquely
mapped reads of all predicted miRNAs from our
LNCaP dataset comprised more than three quarters of
the predicted RNAseq reads. More than 99.8% reads
are mapped into one, two or three genomic loci.
We tested miRDeep* using the miRDeep2 small
RNAseq dataset (17) to further assess miRdeep* in pre-
dicting novel miRNA. Significantly, these data were
generated before and after inducing anti-dicer in MCF-7
cells to turn off the miRNA biogenesis pathway. The
miRNA predicted by miRDeep* has a lower average
log(FC) compared with miRDeep2, which demonstrates
that these novel miRNAs are more likely to be generated
from the miRNA biogenesis pathway (Figure 3B and
Table 3). This is further supported as the percentage of
miRNA with a negative fold change after Dicer
knockdown, which indicates that mature miRNA are no
longer produced, is greater than that of miRDeep2.
However, miRDeep2 was able to predict more novel
miRNA than miRDeep*.
We have also assessed whether miRDeep* is able to
detect novel miRNA that was previously reported in two
prostate cancers from a small RNAseq dataset. Of the 28
novel miRNAs detected by Martens-Uzunova et al. (11),
miRDeep* was able to detect seven of these in our LNCaP
prostate cancer cells (Supplementary Table S4).
We have further evaluated the performance of
miRDeep* on 7 of the 406 small RNAseq datasets
derived from a breast cancer study (38). The seven
datasets analyzed composed of four different stages of
the disease. The precision of all but one of these seven
datasets is >83% (Supplementary Table S7). Similarly,
the recall of all seven datasets is >80% (Supplementary
Table S7). Most of the miRNAs that were undetected by
miRDeep* have very low number of reads, and collect-
ively, these results are consistent with our LNCaP
analyses.
Validation of miRDeep*-predicted miRNA
Five novel miRNAs predicted by miRDeep* (2 miRNA
with the highest score, novel 1 and 2 and three of the
higher expressing miRNA with more than 100 reads,
novels 3, 4 and 5) from our LNCaP RNAseq dataset
were chosen for validation using SL-RT TaqMan PCR.
However, one of these novel miRNAs (novel 5) could not
be amplified, including the synthesized positive control
oligonucleotide. Consequently, further validation was
only carried out for the other four novel miRNA predicted
by miRDeep*. The highly expressed hsa-miR-29a, an
androgen-regulated miRNA in prostate cancer cells, and
hsa-let-7a-2 expression were also assessed by SL-RT
TaqMan PCR. The novel 1 miRNA maps to
Chromosome 17 and is located within and antisense of
the AATK and hsa-miR-338 genes (Figure 4a). The novel
2 miRNA maps to Chromosome X and is located within
the EDA gene (Figure 4a). The novel 3 miRNA is located
antisense of NT5DC1, and the novel 4 miRNA is located
within and antisense of ARHGAP44 (Figure 4a). The
novel 1 and 2 miRNAs were predicted by all methods
(miRDeep*, miRDeep2, miRDeep, miRanalyzer,
Table 1. Comparative analysis of the sensitivity and specificity of miRDeep*
miRDeep* miRDeep2 miRDeep miRanalyzer miRTRAP MIReNA
Mock treated
Number of known miRNA found in raw RNAseq readsa,b 240 240 240 240 240 240
Number of predicted miR 208 272 203 1063 298 162
Number of predicted miR in miRBaseb 173 208 164 215 158 77
Number of predicted novel miR 35 64 39 848 140 85
Precision 83.17% 76.47% 80.79% 20.23% 53.02% 47.53%
Recall 72.08% 86.67% 68.33% 89.58% 65.83% 32.08%
R1881 treated
Number of known miRNA found in raw RNAseq readsa,b 285 285 285 285 285 285
Number of predicted miR 237 320 235 1321 345 190
Number of predicted miR in miRBaseb 192 229 180 261 175 88
Number of predicted novel miR 45 91 55 1060 170 102
Precision 81.01% 71.56% 76.60% 19.76% 50.72% 46.32%
Recall 67.37% 80.35% 63.16% 91.58% 61.40% 30.88%
Precision=Number of predicted miRNA in miRBase/Number of predicted miRNA. Recall=Number of predicted miRNA in miRBase/RNAseq
reads found in miRBase.
aWhere at least 5 raw RNAseq reads map to each known miRNA in miRBase version 13.
bmiRBase version 13.
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miRTRAP and MIReNA) in both mock and R1881
datasets (Supplementary Table S5). The novel 3 miRNA
was predicted by miRDeep* and miRDeep, and the novel
4 miRNA was predicted by only miRDeep* in both mock
and R1881 datasets and by miRDeep in mock dataset.
SL-RT TaqMan PCR was able to specifically detect the
mature miRNA as TaqMan PCR on random hexamer-
generated cDNA using the same quantity of synthetic
miRNA resulted in a much higher Ct value compared
with PCR on cDNA generated from SL oligonucleotides
targeting each novel miRNA (Supplementary Table S6).
Of the six miRNAs assessed by SL-RT TaqMan PCR,
only hsa-miR29a was significantly upregulated by R1881
in LNCaP cells, which is consistent with previous studies
(Figure 4a). Conversely, the novel 2 miRNA was signifi-
cantly down-regulated by R1881 (Figure 4a). The
pre-miRNA secondary structure of these novel miRNAs
and their expression levels (for ethanol-treated cells) are
shown in Figure 4b. The expression of pre-miRNA for
each of these novel miRNA using qualitative RT–PCR
(Figure 4c) demonstrates that they are synthesized and
processed in the classical pri- and pre-miRNA biogenesis
pathways.
DISCUSSION
miRNAs are a class of ncRNA that are increasingly found
to be important in many aspects of normal developmental
and disease processes. Indeed, the mechanisms through
which miRNA mediate the post-transcriptional effects
appear to extend beyond the classical translational repres-
sion and RNA degradation pathways. Recent studies have
discovered that miRNA might also be involved in
regulating the actions of ribonucleoprotein complexes in
a mechanism that is independent of the canonical RISC
pathway (1). The levels of a number of miRNA have been
reported to be deregulated in many complex diseases, such
as cancer, and at least 26 altered miRNA profiles have
already been described in prostate cancer alone (4). In
fact, a recent study has identified a panel of miRNA,
which can be used to differentiate between normal and
prostate cancer cells (39). These recent discoveries high-
light the importance of identifying miRNA that are ex-
pressed in normal and disease contexts so that
therapeutic and disease management strategies can be
employed.
We have taken advantage of the recent advances made
in next-generation RNAseq to profile the androgen-
regulated small-RNA transcriptome in prostate cancer
cells. We investigated the miRNA expression profile in
our small RNAseq dataset on the basis of the importance
of miRNA in prostate cancer, and the role of androgens in
prostate cancer progression (40). However, to use the
existing miRNA prediction tools—miRDeep and its
varieties (16, 41, 42)—we have to pre-process the data
using several other application tools such as a read align-
ment tool and a RNA secondary structure tool. Moreover,
some miRNA, such as miR-25 and miR-200a, were found
to be highly expressed in our LNCaP dataset by
miRDeep* but were not detected by miRDeep due to
improper excision of the pre-miRNA region in those al-
gorithms. Importantly, Martens et al., discovered novel
miRNA in their study, and miRDeep* was able to
detect seven of these novel miRNA in our LNCaP small
RNAseq data.
miRDeep* is a standalone, one-click, integrated,
RNAseq-based miRNA prediction tool. This application
does not require any pre-installed computational tools,
such as a RNA secondary structure tool or a genome
alignment tool. These tools are built into miRDeep*
using pure Java coding. Therefore, this application can
be easily executed on any platform (Linux, Windows
and MacOS). Although there are several RNAseq-based
miRNA computational tools, we provide the first truly
intuitive and most user-friendly tool that has a graphics
display output showing the RNAseq reads relative to the
pre-miRNA secondary structure. This display also illus-
trates miRNA isoforms, including the copy numbers for
each variant. This application also accepts aligned reads in
SAM/BAM format as input files. One of the major advan-
tages of miRDeep* in reducing analysis time is that, unlike
other web-based algorithms, miRDeep* is a standalone
application where all the data are readily accessible to
the user, making it easy to adjust the source code and to
change the miRNA prediction strategy. Moreover,
miRDeep* is not affected by other users because this
standalone application runs on a local machine.
Sequence alignment and RNA secondary structure
modeling of 3 million reads takes only 3 h to perform
Table 2. Multiple mapped reads
Mapping MOCK R1881
Reads Percentage Reads Percentage
1 582 762 82.14 864 909 74.22
2 44 545 6.28 79 788 6.85
3 81 175 11.44 219 510 18.84
4 675 0.10 919 0.08
5 25 0.00 34 0.00
6 174 0.02 39 0.00
7 50 0.01 0 0.00
8 58 0.01 22 0.00
9 14 0.00 15 0.00
10 0 0.00 9 0.00
11 0 0.00 38 0.00
12 0 0.00 36 0.00
13 0 0.00 5 0.00
14 0 0.00 0 0.00
15 0 0.00 0 0.00
16 0 0.00 24 0.00
17 15 0.00 0 0.00
18 0 0.00 39 0.00
Table 3. Difference between before and after anti-dicer for novel
miRs identified by miRDeep* and miRDeep2
Average
log(FC)
miRs with negative
FC (%)
Number of
novel miRs
miRDeep* 2.74 85.70 98
miRDeep2 1.01 74.79 234
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on miRDeep* using a PC windows XP with 2.5GHz CPU
and 4G RAM, whereas a similar analysis can take up to
12 h using the web-based miRanalyzer and miRTRAP and
MIReNA.
Many of the current small RNAseq-based miRNA pre-
diction tools have been influenced by the highly effective
miRDeep tool (16, 43). For example, deepBase that has a
repository of 2038 predicted miRNAs (44) used 185
publically available small RNAseq experiments and the
miRDeep algorithm to compile the database. seqBuster
(45) provides a web-based and standalone application to
analyse known miRNA variants. miRanalyzer (46) is a
web-based application that finds known and novel
miRNAs from sequence data and uses a random forest
machine learning algorithm to predict novel miRNAs.
miRNAKey (47) and DSAP (48) determine the differential
known miRNA expression from deep sequence data. More
recently, the miRDeep2 program was introduced, which
improved on the original miRDeep algorithm as well as
other functions such as graphical output. Coincidentally,
we were independently developing miRDeep* in parallel
with miRDeep2, using similar algorithms to identify the
precursor miRNA, and extra functionalities such as a
graphical output. However, miRDeep* has slightly differ-
ent approaches including a dynamic graphical output as
opposed to miRDeep2’s static output.
We have benchmarked miRDeep* against miRDeep,
miRDeep2, miRTRAP, mIReNA and miRanalyzer
using the same small RNAseq reads. Our analyses was
carried out under no a priori knowledge that the dataset
was derived from human prostate cancer cells and so at-
tempted to find all possible miRNAs. miRanalyzer was
able to detect approximately 5-fold more miRNA from
the same dataset compared with miRDeep*, miRDeep2
and miRDeep; however, the precision for miRanalzer
was only 20%. miRDeep* had slightly better precision
(less than 10%) and recall (less than 5%) compared with
miRDeep. Interestingly, miRDeep2 had lower precision
compared with the original miRDeep for our dataset.
However, the recall of miRDeep2 was much better than
miRDeep* (mock: 27%; R1881: 18%) and miRDeep
(mock: 30%; R1881: 23%). The improved predictive
ability of miRDeep* was further supported by using a
dataset whereby the classical miRNA biogenesis
pathway was turned off through Dicer knock-down.
Using this dataset, bona fide mature miRNA are less
likely to be predicted in cells where Dicer was knocked
out. Our results demonstrated that miRDeep* is less
likely to result in false-positive predictions of miRNA
compared with miRDeep2. MiRTRAP detected similar
numbers of miRNA from the same dataset with
miRDeep2, but its precision was lower than miRDeep2.
However, miRTRAP has a better performance than
MIReNA in terms of precision and recall in our
datasets. Finally, we have analysed seven other small
RNAseq datasets from breast cancers using miRDeep*
and found that the performance (precision and recall) is
similar to the results from our LNCaP datasets.
Of the four miRNAs chosen for validation by SL-RT
TaqMan PCR, one (novel 4) was predicted solely by
miRDeep*. Thus, miRDeep* is both more precise at
Figure 4. Validation of miRDeep*-predicted novel miRNA.
(a) Validation was carried out using stem-loop TaqMan PCR for
four novel miRNA (novel 1–4), and hsa-miR-29a and hsa-let-7a-2,
which served as positive controls. Small RNAseq was performed on
RNA that was extracted from LNCaP prostate cancer cells that were
treated with ethanol (mock) or androgen (1 nM R1881) for 48 h.
Represented is the mean expression±SE from three independently
treated cells. (b) Representation of the pre-miRNA secondary structure
predicted by miRDeep*, including the location of the mature miRNA
(red nucleotides). Also shown are the locations and number of RNAseq
reads (lines above and below the predicted pre-miRNA). (c) Qualitative
RT–PCR showing expression of novel 1, 2, 3, and 4 pre-miRNA. No
reverse transcriptase (RT) controls were included to ensure that
genomic DNA (gDNA) was not amplified. gDNA and a negative
template (H2O) were included as positive and negative controls,
respectively.
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predicting miRNA from small RNAseq reads and having
greater capacity to detect novel miRNA compared with
miRDeep and miRDeep2. Moreover, miRDeep* is able to
predict miRNA that are formed from the classical pri- and
pre-miRNA biogenesis pathways as shown by the detec-
tion of pre-miRNA in our validation experiments.
In conclusion, we have developed miRDeep* that is a
useful tool for predicting novel miRNA from small
RNAseq. miRDeep* is the first application for predicting
miRNAs without any pre-installed software and has better
predictive capabilities compared with miRDeep and
miRDeep2. miRDeep* also offers numerous user-friendly
and functional advantages, such as full Java coding, which
makes it suitable for use with many operating systems, as
well as displaying RNAseq reads and the number of reads
relative to the predicted pre-miRNA. Importantly, this
tool provides the target prediction for both known and
novel miRNAs, unlike most tools, which do not provide
target prediction for novel miRNAs. Given the role of
miRNA in many biological contexts, including prostate
cancer, we propose that miRDeep* will be an extremely
useful tool for researchers.
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